frontiers | Frontiers in Cellular and Infection Microbiology

TYPE Correction
PUBLISHED 23 June 2023
DOI 10.3389/fcimb.2023.1226054

OPEN ACCESS

EDITED AND REVIEWED BY
Daniel Salamango,
Stony Brook University, United States

*CORRESPONDENCE
Deepti Parashar
deeptiparasharster@gmail.com
Sarah Cherian
sarahcherian100@gmail.com

†These authors have equally contributed to this work

RECEIVED 20 May 2023
ACCEPTED 22 May 2023
PUBLISHED 23 June 2023

CITATION
Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) Corrigendum: Drug repurposing approach against chikungunya virus: an *in vitro* and *in silico* study. *Front. Cell. Infect. Microbiol.* 13:1226054. doi: 10.3389/fcimb.2023.1226054

Corrigendum: Drug repurposing approach against chikungunya virus: an *in vitro* and *in silico* study

Bhagyashri Kasabe[1†], Gunwant Ahire[2†], Poonam Patil[2], Madhura Punekar[2], Kusuma Sai Davuluri[2], Mahadeo Kakade[2], Kalichamy Alagarasu[2], Deepti Parashar[2*] and Sarah Cherian[1*]

[1]Bioinformatics Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India, [2]Dengue & Chikungunya Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India

KEYWORDS

chikungunya virus (CHIKV), drug repurposing, structural and non-structural proteins, *in silico* screening, *in vitro* validation

A corrigendum on

Drug repurposing approach against chikungunya virus: an *in vitro* and *in silico* study

by Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) *Front. Cell. Infect. Microbiol.* 13:1132538. doi: 10.3389/fcimb.2023.1132538

In the published article, there was an error in Table 4 as published. The target for metyrapone was listed twice while the target for lomibuvir was missed. The corrected Table 4 and its caption [Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose] appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 4 Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose.

Compound	Potential binding viral targets		Docking score	Binding energy (kcal/mol)	Ligand Efficiency (kcal/ mol)
2-Fluroadenine	(a) NSP3 	(b) Envelope 	(a)-6.966 (b)-2.958	-37.69 -25.51	-11.091 -5.632
Doxorubicin	(a) Envelope 	(b) MTase 	(a)-4.76 (b)-6.069 (c)-3.547	-77.88 -77.55 -77.21	-13.179 -15.343 -13.297
	(c) NSP3 				

(Continued)

10.3389/fcimb.2023.1226054

TABLE 4 Continued

Compound	Potential binding viral targets		Docking score	Binding energy (kcal/mol)	Ligand Efficiency (kcal/ mol)
Felbiac	(a) RdRp 	(b) NSP3 	(a)-4.332 (b)-6.115	-44.3 -39.72	-11.74 -10.529
Metyrapone	(a) Envelope 	(b) NSP3 	(a)-4.358 (b)-6.498	-51.12 -50.81	-12.521 -13.255
Enalprilat	(a) NSP3 	(b) Protease 	(a)-7.476 (b)-4.02	-60.97 -55.33	-14.452 -11.234

(Continued)

10.3389/fcimb.2023.1226054

10.3389/fcimb.2023.1226054

TABLE 4 Continued

Compound	Potential binding viral targets		Docking score	Binding energy (kcal/mol)	Ligand Efficiency (kcal/ mol)
Emetine	a) Helicase 	(b) Envelope 	(a)-4.086 (b)-4.238	-74.25 -71.81	
Resveratrol	(a) NSP3 	(b) Envelope 	(a)-6.22 (b)-4.675	-56.45 -47.43	-14.72 -11.734
Lombubivir	(a) NSP3 	(b) Capsid 	(a)-5.573 (b)-4.759	-81.13 -78.83	

Publisher's note